IXC — Invex Therapeutics Income Statement
0.000.00%
Last trade - 00:00- AU$5.64m
- -AU$0.17m
- AU$1.70m
- 78
- 65
- 42
- 65
Annual income statement for Invex Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.166 | 0.159 | 0.262 | 1.26 | 1.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 3.53 | 2.44 | 4.22 | 9.01 | 3.35 |
| Operating Profit | -3.36 | -2.28 | -3.95 | -7.75 | -1.64 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.36 | -2.28 | -3.95 | -7.75 | -1.64 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.36 | -2.28 | -3.95 | -7.75 | -1.64 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.36 | -2.28 | -3.95 | -7.75 | -1.64 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.36 | -2.28 | -3.95 | -7.75 | -1.64 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.055 | -0.03 | -0.053 | -0.103 | -0.022 |
| Special Dividends per Share |